Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The WAVEsystem with the WAVEcontrol 4.0 embedded
Ministry of Ayush has fast tracked up-gradation and construction of various Ayush Infrastructure across the country
he US FDA has issued six observations pursuant to the completion of the audit.
He was appointed a Board member and the Chairman in 2012.
Subscribe To Our Newsletter & Stay Updated
